Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, ...

MINNEAPOLIS, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,United Kingdom ,Philadelphia ,British ,Tammy Groene ,Elizabeth Bruckheimer ,Michael Hogarty ,Nasdaq Stock Market ,Nasdaq ,European Union ,Advances In Neuroblastoma Therapy Consortium ,Panbela Therapeutics Inc ,Children Oncology Group Phase ,British Journal ,New Advances ,Neuroblastoma Therapy Consortium ,Vice President ,Chief Scientific Officer ,Oncology Group Phase ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Region ,